Blog examines use of controversial HIV drug in Malawi

This post in the Center for Global Health Policy's "Science Speaks" blog examines the use of stavudine, "also known as d4T, an antiretroviral treatment that was dropped in wealthy countries years ago and that the World Health Organization has recommended stop being included in treatment programs," to treat HIV in Malawi. "[W]hile children and pregnant or breastfeeding women, as well as tuberculosis patients have access to less toxic treatments, stavudine continues to be the first treatment supplied to most Malawi patients under the terms of the country's grant from the Global Fund to Fight AIDS, Tuberculosis and Malaria," the blog writes, adding, "In a letter [.pdf] to Global Fund General Manager Gabriel Jaramillo and [U.S. Global AIDS Coordinator Ambassador] Eric Goosby, the Centre for Development of People (CEDEP), Health GAP (Global Access Project), and the Malawi Network of People Living with HIV/AIDS (MANET+) are asking the Global Fund to find a way to switch to first line treatment in Malawi that is acceptable to patients and World Health Organization standards" (8/15).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Proof-of-concept animal studies demonstrate a step forward in the fight against HIV